Published in Eur J Pharmacol on April 10, 1990
Maternal food restriction in the second half of pregnancy affects vascular function but not blood pressure of rat female offspring. Br J Nutr (1999) 1.72
Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol (2001) 1.70
Haemorheological effects of ketanserin, a selective 5-HT2 receptor antagonist, in aged, spontaneously hypertensive dogs. Arch Int Pharmacodyn Ther (1982) 1.13
Streptozotocin diabetes in the pregnant rat induces cardiovascular dysfunction in adult offspring. Diabetologia (1999) 1.09
Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. J Biol Chem (1985) 1.08
Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol (2001) 0.99
Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol (1986) 0.99
Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. J Am Coll Cardiol (1990) 0.96
The role of endogenously formed diacylglycerol in the propagation and termination of platelet activation. A biochemical and functional analysis using the novel diacylglycerol kinase inhibitor, R 59 949. J Biol Chem (1989) 0.95
Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin. Thromb Res (1982) 0.95
The rheological effects of cinnarizine and flunarizine in normal and pathologic conditions. Angiology (1979) 0.94
Pharmacological control of platelet and red blood cell function in the microcirculation. J Cardiovasc Pharmacol (1982) 0.94
Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharmacol (2000) 0.94
Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol (1984) 0.91
Effects of anti-inflammatory, anticoagulant and vasoactive compounds on tail bleeding time, whole blood coagulation time and platelet retention by glass beads in rats. Thromb Res (1976) 0.91
Ischemia/reperfusion-induced arrhythmias in anaesthetized rats: a role of Na+ and Ca2+ influx. Eur J Pharmacol (1999) 0.90
Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacology (1984) 0.88
Oxatomide protects Trichinella spiralis infected mice from lethal anaphylaxis. Agents Actions (1978) 0.87
Modulation of airway hyperresponsiveness by thiols in a murine in vivo model of allergic asthma. Inflamm Res (2003) 0.86
Synthetic inhibitors of human tissue kallikrein. Immunopharmacology (1996) 0.86
Platelet activation by endogenous 5-hydroxytryptamine and histamine released by mast cell degranulation with compound 48/80 in the rat. Agents Actions (1983) 0.86
Direct evidence for the contractile capacity of endothelial cells. Thromb Res (1981) 0.85
Blood hyperviscosity in spontaneously hypertensive rats. Thromb Res (1980) 0.84
Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc Res (2001) 0.84
Are there sex-specific differences in ventricular repolarization or in drug-induced early afterdepolarizations in isolated rabbit purkinje fibers? J Cardiovasc Pharmacol (2000) 0.84
Virus-induced airway hyperresponsiveness in the guinea-pig: possible involvement of histamine and inflammatory cells. Br J Pharmacol (1993) 0.83
The synergistic effect of 5-hydroxytryptamine and epinephrine on the human platelet is related to the activation of phospholipase C. Eur J Pharmacol (1993) 0.83
Calcium sensors as new therapeutic targets for airway hyperresponsiveness and asthma. FASEB J (2001) 0.83
Effect of flunarizine on the human red cell shape changes and calcium deposition induced by A 23187. Thromb Res (1982) 0.82
Platelet-mediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker. Biochem Pharmacol (1983) 0.82
Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis. J Cardiovasc Pharmacol (1993) 0.82
Thromboxane A2-induced vascular endothelial cell damage and respiratory smooth muscle cell contraction: inhibition by flunarizine, a Ca2+-overload blocker. Arch Int Pharmacodyn Ther (1985) 0.82
R 56 865, a Na+/Ca(2+)-overload inhibitor, protects against aconitine-induced cardiac arrhythmias in vivo. J Cardiovasc Pharmacol (1993) 0.81
The effect of flunarizine treatment on human red blood cells. Angiology (1979) 0.81
Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung. J Pharmacol Exp Ther (1992) 0.81
Selective vasoconstriction by alniditan in the carotid vascular bed of anaesthetized dogs. Eur J Pharmacol (1996) 0.80
The synergistic effect of serotonin and epinephrine on the human platelet at the level of signal transduction. FEBS Lett (1987) 0.80
Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations. Blood Coagul Fibrinolysis (1991) 0.80
The involvement of 5-HT2-receptor sites in the activation of cat platelets. Thromb Res (1984) 0.80
Demonstration of S2-receptor binding sites on cat blood platelets using [3H]ketanserin. Eur J Pharmacol (1983) 0.80
Protection by flunarizine against endothelial cell injury in vivo. Angiology (1981) 0.80
Nocodazole, a new synthetic antimitotic agent, enhances the production of plasminogen activator by cells in culture. Thromb Res (1977) 0.78
Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis. I. In vitro experiments. Arch Int Pharmacodyn Ther (1975) 0.78
Dissociation of clot retraction from platelet granule fusion and degranulation: an ultrastructural study of Reptilase-human platelet-rich plasma clots. Br J Haematol (1975) 0.78
Platelet-mediated vascular permeability in the rat: a predominant role for 5-hydroxytryptamine. Thromb Res (1985) 0.78
Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH. Thromb Res (1985) 0.77
Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells. Agents Actions (1981) 0.77
Inhibition of Na+/Ca2+ overload with R 56,865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. Eur J Pharmacol (1993) 0.77
Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro. Agents Actions (1986) 0.77
Reduction by flunarizine of the increase of blood viscosity after ischemic forearm occlusion. Arch Int Pharmacodyn Ther (1977) 0.77
Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review. Agents Actions (1984) 0.77
Antiarrhythmic effects of nebivolol in experimental models in vivo. J Cardiovasc Pharmacol (1994) 0.77
Does the antiarrhythmic effect of ischemic preconditioning in rats involve the L-arginine nitric oxide pathway? J Cardiovasc Pharmacol (1995) 0.77
Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist. Arch Int Pharmacodyn Ther (1984) 0.76
The effect of the intracellular calcium chelator Quin-2 on the platelet phosphoinositide metabolism, protein phosphorylation and morphology. Thromb Haemost (1987) 0.76
The protection by ischemic preconditioning against myocardial ischemia- and reperfusion-induced arrhythmias is not mediated by ATP-sensitive potassium channels in rats. Coron Artery Dis (1993) 0.76
Blood platelets in human essential hypertension. Agents Actions (1986) 0.76
S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced anti-platelet effect. Thromb Haemost (1986) 0.75
Reduction in QT dispersion and ventricular arrhythmias by ischaemic preconditioning in anaesthetized, normotensive and spontaneously hypertensive rats. Fundam Clin Pharmacol (1999) 0.75
Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine. Agents Actions (1984) 0.75
Modification of venous stasis thrombosis in the rat by platelet-active drugs and by heparin. Arch Int Pharmacodyn Ther (1976) 0.75
Effects of pharmacological agents on erythrocyte deformability and endothelial cell injury. J Cereb Blood Flow Metab (1982) 0.75
Suppression of PAF-induced bronchoconstriction in the guinea-pig by oxatomide: mechanism of action. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.75
Treatment evaluation of a severe methaqualone intoxication in man. Vet Hum Toxicol (1979) 0.75
Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis II. In vivo experiments. Arch Int Pharmacodyn Ther (1975) 0.75
Toxicological results and criteria of death. J Pharm Belg (1977) 0.75
Differential vasoreactivity to the thromboxane A2 mimic U-46619 of collateral and normal peripheral blood vessels in situ perfused rat hindquarters. Blood Vessels (1989) 0.75
Oxatomide protects against degranulation of rat peritoneal mast cells during in vitro challenge with antigen or compound 48/80. Ultrastructural aspects. Agents Actions (1981) 0.75
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs. J Cardiovasc Pharmacol (1995) 0.75
Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries. J Lipid Mediat (1992) 0.75
Inhibition by suprofen and other non-narcotic analgesic drugs of the effects of prostaglandin precursor on isolated tissues and platelets. Arch Int Pharmacodyn Ther (1976) 0.75
Vernolepin and platelet aggregation: further studies on the mechanism of action. Arch Int Pharmacodyn Ther (1982) 0.75
Betamethasone prevents virus-induced airway inflammation but not airway hyperresponsiveness in guinea pigs. Clin Exp Allergy (1999) 0.75
Prolonged course of hepatic granulomatous disease due to Bartonella henselae infection. Acta Gastroenterol Belg (2017) 0.75
Vascular reactivity and calcium-entry blockers. Adv Cyclic Nucleotide Protein Phosphorylation Res (1984) 0.75
QT and JT dispersion in the drug-induced long QT syndrome in anaesthetized rabbits is accurately detected by a three-lead surface ECG measurement. J Pharmacol Toxicol Methods (2004) 0.75
Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets. Eur J Pharmacol (1990) 0.75
Effect of lorcainide, a new antiarrhythmic compound, on the changes in heart rhythm induced by intravenous injection of adenosine-5'-diphosphate in rats. Arch Int Pharmacodyn Ther (1978) 0.75
Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist. Blood Coagul Fibrinolysis (1991) 0.75
5-Hydroxytryptamine dominates over thromboxane A2 in reducing collateral blood flow by activated platelets. Am J Physiol (1993) 0.75
Determination of 6-keto-PGF1 alpha, 2,3-dinor-6-keto-PGF1 alpha, thromboxane B2, 2,3-dinor-thromboxane B2, PGE2, PGD2 and PGF2 alpha in human urine by gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr (1991) 0.75
The synergistic effect of serotonin and epinephrine at the level of signal transduction. J Cardiovasc Pharmacol (1988) 0.75
3H-Ketanserin labels serotonin S2-receptor binding sites on cat blood platelets. Arch Int Pharmacodyn Ther (1983) 0.75
Enhanced platelet turnover and prostaglandin production in spontaneously hypertensive rats. Thromb Res (1982) 0.75
Continuous inhibition of the platelet S2-serotonergic receptors during the long term administration of ketanserin. Thromb Res (1986) 0.75
Gas chromatographic-mass spectrometric determination of 11-dehydrothromboxane B2 in human urine. J Chromatogr (1992) 0.75
Prolonged course of hepatic granulomatous disease due to Bartonella henselae infection. Acta Gastroenterol Belg (2017) 0.75
Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans. J Cardiovasc Pharmacol (1985) 0.75
Vernolepin: an antiplatelet compound of natural origin. Naunyn Schmiedebergs Arch Pharmacol (1985) 0.75
The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication. Int Angiol (1993) 0.75
The inhibition of ischemic lesions of the rat gastric mucosa by a novel serotonin-antagonist: a light and electron microscopic study. Angiology (1981) 0.75
Class IV Ca2+ antagonists do not affect lipid peroxidation in singlet oxygen challenged cardiomyocytes. Cell Biol Int Rep (1990) 0.75
Effect of lidoflazine (R 7904) on human platelet function in vitro. Thromb Diath Haemorrh (1972) 0.75
Microvascular permeability increase in rat skin: inhibition by flunarizine, a Ca2+ entry blocker. Blood Vessels (1986) 0.75
Vasoconstrictor expression of human platelet-vessel wall interactions: inhibition by the Ca2+ entry blocker flunarizine. Eur J Pharmacol (1987) 0.75
Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man. Thromb Haemost (1992) 0.75
Activated reptilase clot retraction of dog platelet-rich plasma: differences with human platelet-rich plasma. Scand J Haematol (1975) 0.75